Gland Pharma Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 28, 2025
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma held its 47th AGM on August 28, 2025, where newly appointed Executive Chairman Srinivas Sadu and new CEO Shyamakant Giri presented the company's FY25 performance and strategic roadmap. Consolidated revenue stood at ₹56,165 million (down 1% YoY), with EBITDA of ₹12,689 million at a 23% margin, and PAT of ₹6,985 million (down 10% YoY). The core base business, excluding Cenexi, was the growth engine with ₹41,248 million in revenue and a strong EBITDA margin of 35%, up from 34% in FY24. The Cenexi acquisition remained a drag, posting a ₹1,761 million EBITDA loss on ₹14,916 million in revenue, though management said a turnaround had begun in Q1'26. The US market contributed ₹30,387 million, the company launched 31 new molecules, and R&D spend was ₹1,922 million (4.7% of base revenue). US FDA issued EIRs for its Dundigal and Pashamylaram facilities, reinforcing its clean compliance track record.
The leadership transition and steady core business margin expansion (34% to 35% EBITDA) are positives, but the 10% drop in consolidated PAT and continued Cenexi losses may weigh on near-term sentiment. Investors will watch for execution on the biologics CDMO foray, complex product pipeline (~USD 6.5 billion opportunity), and any concrete M&A action under the new CEO.